Theravance Biopharma Inc - ESG Rating & Company Profile powered by AI
Jump to the end of the webpage for potential risks for Theravance Biopharma Inc based on industry, geography and size. If you are employed by Theravance Biopharma Inc and you would like to licence your Sustainability rating, please contact us. This analysis of Theravance Biopharma Inc incorporates data points from across the internet as well as from available disclosures by Theravance Biopharma Inc.
Theravance Biopharma Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.3; made up of an environmental score of 2.0, social score of 1.6 and governance score of 3.2.
2.3
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1512 | Sol Gel Technologies Ltd | 2.4 | Medium |
1512 | Windtree Therapeutics Inc | 2.4 | Medium |
1529 | Theravance Biopharma Inc | 2.3 | Medium |
1529 | ANI Pharmaceuticals Inc | 2.3 | Medium |
1529 | Aarti Drugs Ltd | 2.3 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Theravance Biopharma Inc have an accelerator or VC vehicle to help deliver innovation?
Does Theravance Biopharma Inc disclose current and historical energy intensity?
Does Theravance Biopharma Inc report the average age of the workforce?
Does Theravance Biopharma Inc reference operational or capital allocation in relation to climate change?
Does Theravance Biopharma Inc disclose its ethnicity pay gap?
Does Theravance Biopharma Inc disclose cybersecurity risks?
Does Theravance Biopharma Inc offer flexible work?
Does Theravance Biopharma Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Theravance Biopharma Inc disclose the number of employees in R&D functions?
Does Theravance Biopharma Inc conduct supply chain audits?
Does Theravance Biopharma Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Theravance Biopharma Inc conduct 360 degree staff reviews?
Does Theravance Biopharma Inc disclose the individual responsible for D&I?
Does Theravance Biopharma Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Theravance Biopharma Inc disclose current and / or historical scope 2 emissions?
Does Theravance Biopharma Inc disclose water use targets?
Does Theravance Biopharma Inc have careers partnerships with academic institutions?
Did Theravance Biopharma Inc have a product recall in the last two years?
Does Theravance Biopharma Inc disclose incidents of discrimination?
Does Theravance Biopharma Inc allow for Work Councils/Collective Agreements to be formed?
Has Theravance Biopharma Inc issued a profit warning in the past 24 months?
Does Theravance Biopharma Inc disclose parental leave metrics?
Does Theravance Biopharma Inc disclose climate scenario or pathway analysis?
Does Theravance Biopharma Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Theravance Biopharma Inc disclose the pay ratio of women to men?
Does Theravance Biopharma Inc support suppliers with sustainability related research and development?
Does Theravance Biopharma Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Theravance Biopharma Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Theravance Biopharma Inc involved in embryonic stem cell research?
Does Theravance Biopharma Inc disclose GHG and Air Emissions intensity?
Does Theravance Biopharma Inc disclose its waste policy?
Does Theravance Biopharma Inc report according to TCFD requirements?
Does Theravance Biopharma Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Theravance Biopharma Inc disclose energy use targets?
Does Theravance Biopharma Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Theravance Biopharma Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Theravance Biopharma Inc
These potential risks are based on the size, segment and geographies of the company.
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.